CDK2 and breast carcinoma: In fact, several studies have shown that E2 controls the Cyclin D1, c-Myc, CDK2, CDK4, and CDK inhibitors in MCF-7 breast cancer cells, thus promoting the progression from the G1 to S phase of the cell cycle [76,77].